Additional Information
Book Details
Abstract
With an approach to learning as progressive as its content, Rau’s Respiratory Care Pharmacology, 8th Edition simplifies the process of learning challenging pharmacology material like never before. Rau’s effective approach uses broken-down terminology, relatable explanations, reader-friendly writing, and additional workbook guidance to help you easily master the text’s cutting-edge content – which includes the latest terms, pronunciations, in-depth sleep pharmacology, reality-based case studies, and SOAP assessment opportunities. Plus, the online interactive flashcards and audio pronunciation glossary offer additional learning formats tailored to your digital preferences.
- Improved readability makes it easier for you to grasp difficult material.
- Expanded! Key terms and definitions include over 275 terms with pronunciations.
- Companion workbook offers a wide range of activities that help you apply knowledge gained from the core text and break down more difficult concepts beyond NBRC style multiple-choice questions.
- Clinical Scenarios with follow-up SOAP assessment provide you with a reality-based patient case study and an opportunity to indicate standardized treatment.
- Inside back cover offers a quick-reference list of the most commonly used abbreviations in pharmacology with full application.
- Full-color format draws out special features and creates a more reader-friendly text.
- Glossary aids your comprehension of pharmacology terminology.
- Learning objectives parallel the recall, analysis, and application levels tested on the NBRC exam to prepare you for credentialing.
- Key terms with definitions enable you to quickly master essential terminology.
- Key Points boxes guide you in preparing for tests by identifying the most important concepts in each chapter.
- Self-assessment questions allow you to test yourself on key information within the chapter.
- Student Resources on Evolve, including an audio glossary and electronic flashcards, provide opportunities to hone your understanding of respiratory pharmacology concepts.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| FRONT COVER | Cover | ||
| RAU’S RESPIRATORY CARE PHARMACOLOGY, EIGHTH EDITION | iii | ||
| COPYRIGHT PAGE | iv | ||
| CONTRIBUTORS | vii | ||
| REVIEWERS | ix | ||
| FOREWORD | xi | ||
| PREFACE | xiii | ||
| ACKNOWLEDGMENTS | xv | ||
| TABLE OF CONTENTS | xvii | ||
| UNIT ONE Basic Concepts and Principles in Pharmacology | 1 | ||
| Chapter 1 Introduction to Respiratory Care Pharmacology | 2 | ||
| Pharmacology and the Study of Drugs | 3 | ||
| Naming Drugs | 4 | ||
| Sources of Drug Information | 5 | ||
| Sources of Drugs | 5 | ||
| Process for Drug Approval in the United States | 5 | ||
| The Prescription | 7 | ||
| Respiratory Care Pharmacology: An Overview | 9 | ||
| References | 10 | ||
| Chapter 2 Principles of Drug Action | 11 | ||
| Drug Administration Phase | 12 | ||
| Pharmacokinetic Phase | 14 | ||
| Pharmacodynamic Phase | 23 | ||
| Pharmacogenetics | 29 | ||
| References | 30 | ||
| Chapter 3 Administration of Aerosolized Agents | 31 | ||
| Physical Principles of Inhaled Aerosol Drugs | 32 | ||
| Aerosol Generators for Drug Delivery | 37 | ||
| Selecting an Aerosol Device | 56 | ||
| Clinical Application of Aerosol Delivery Devices | 56 | ||
| References | 62 | ||
| Chapter 4 Calculating Drug Doses | 65 | ||
| Systems of Measure | 65 | ||
| Calculating Doses from Prepared-Strength Solutions | 67 | ||
| Calculating Doses from Percentage-Strength Solutions | 69 | ||
| References | 75 | ||
| Chapter 5 Central and Peripheral Nervous Systems | 76 | ||
| Nervous System | 77 | ||
| Autonomic Branches | 77 | ||
| Parasympathetic Branch | 80 | ||
| Cholinergic Agents | 82 | ||
| Anticholinergic Agents | 83 | ||
| Sympathetic Branch | 84 | ||
| Sympathomimetic (Adrenergic) and Sympatholytic (Antiadrenergic) Agents | 88 | ||
| Neural Control of Lung Function | 88 | ||
| References | 94 | ||
| UNIT TWO Drugs Used to Treat the Respiratory System | 95 | ||
| Chapter 6 Adrenergic (Sympathomimetic) Bronchodilators | 96 | ||
| Clinical Indications for Adrenergic Bronchodilators | 97 | ||
| Specific Adrenergic Agents and Formulations | 97 | ||
| Mode of Action | 107 | ||
| Routes of Administration | 109 | ||
| Adverse Side Effects | 111 | ||
| Compatibility of Other Agents with Bronchodilators | 115 | ||
| β-Agonist Controversy | 115 | ||
| Respiratory Care Assessment of β-Agonist Therapy | 116 | ||
| References | 117 | ||
| Chapter 7 Anticholinergic (Parasympatholytic) Bronchodilators | 119 | ||
| Clinical Indications for Use | 120 | ||
| Specific Anticholinergic (Parasympatholytic) Agents | 120 | ||
| Clinical Pharmacology | 122 | ||
| Mode of Action | 125 | ||
| Adverse Effects | 127 | ||
| Clinical Application | 128 | ||
| Respiratory Care Assessment of Anticholinergic Bronchodilator Therapy | 131 | ||
| References | 133 | ||
| Chapter 8 Xanthines | 135 | ||
| Clinical Indications for the Use of Xanthines | 135 | ||
| Specific Xanthine Agents | 136 | ||
| General Pharmacologic Properties | 136 | ||
| Titrating Theophylline Doses | 139 | ||
| Respiratory Care Assessment of Xanthines | 142 | ||
| References | 143 | ||
| Chapter 9 Mucus-Controlling Drug Therapy | 145 | ||
| Drug Control of Mucus: A Perspective | 146 | ||
| Physiology of the Mucociliary System | 147 | ||
| Nature of Mucus Secretion | 151 | ||
| Physical Properties of Mucus | 154 | ||
| Mucoactive Agents | 155 | ||
| Mucolytics and Expectorants | 156 | ||
| Mucokinetic Agents | 159 | ||
| Mucoregulatory Medications | 160 | ||
| Other Mucoactive Agents | 160 | ||
| Gene Therapy | 161 | ||
| Using Mucoactive Therapy with Physiotherapy and Airway Clearance Devices | 161 | ||
| Future Mucus-Controlling Agents | 163 | ||
| Respiratory Care Assessment of Mucoactive Drug Therapy | 164 | ||
| References | 166 | ||
| Chapter 10 Surfactant Agents | 171 | ||
| Physical Principles | 172 | ||
| Clinical Indications for Exogenous Surfactants | 172 | ||
| Identification of Surfactant Preparations | 173 | ||
| Specific Exogenous Surfactant Preparations | 176 | ||
| Mode of Action | 178 | ||
| Clinical Outcome | 178 | ||
| Hazards and Complications of Surfactant Therapy | 178 | ||
| Future Directions in Surfactant Therapy | 179 | ||
| Respiratory Care Assessment of Surfactant Therapy | 179 | ||
| References | 180 | ||
| Chapter 11 Corticosteroids in Respiratory Care | 181 | ||
| Clinical Indications for Use of Inhaled Corticosteroids | 182 | ||
| Identification of Aerosolized Corticosteroids | 182 | ||
| Physiology of Corticosteroids | 182 | ||
| Nature of Inflammatory Response | 185 | ||
| Aerosolized Corticosteroids | 187 | ||
| Pharmacology of Corticosteroids | 190 | ||
| Hazards and Side Effects of Steroids | 192 | ||
| Clinical Application of Aerosol Steroids | 195 | ||
| Respiratory Care Assessment of Inhaled Corticosteroid Therapy | 196 | ||
| References | 197 | ||
| Chapter 12 Nonsteroidal Antiasthma Agents | 200 | ||
| Clinical Indications for Nonsteroidal Antiasthma Agents | 201 | ||
| Identification of Nonsteroidal Antiasthma Agents | 201 | ||
| Mechanisms of Inflammation in Asthma | 201 | ||
| Cromolyn (Mast Cell–Stabilizing) Agents | 204 | ||
| Antileukotriene Agents | 206 | ||
| Respiratory Care Assessment of Nonsteroidal Antiasthma Agents | 214 | ||
| References | 215 | ||
| Chapter 13 Aerosolized Antiinfective Agents | 217 | ||
| Clinical Indications for Aerosolized Antiinfective Agents | 218 | ||
| Identification of Aerosolized Antiinfective Agents | 218 | ||
| Respiratory Care Assessment of Aerosolized Antiinfective Agents | 231 | ||
| References | 234 | ||
| Chapter 14 Antimicrobial Agents | 236 | ||
| Principles of Antimicrobial Therapy | 237 | ||
| Antibiotics | 241 | ||
| Antimycobacterials | 253 | ||
| Antifungals | 255 | ||
| Antiviral Agents | 258 | ||
| Respiratory Care and Assessment of Antibiotic Therapy | 261 | ||
| References | 262 | ||
| Chapter 15 Cold and Cough Agents | 263 | ||
| Sympathomimetic (Adrenergic) Decongestants | 264 | ||
| Antihistamine Agents | 265 | ||
| Expectorants | 267 | ||
| Cough Suppressants (Antitussives) | 268 | ||
| Cold Compounds | 269 | ||
| Respiratory Care Assessment of Cold and Cough Agents | 270 | ||
| References | 271 | ||
| Chapter 16 Selected Agents of Pulmonary Value | 272 | ||
| α₁-PROTEINASE INHIBITOR (HUMAN) | 273 | ||
| Respiratory Care Assessment of Therapy of α₁-Proteinase Inhibitor (Human) | 274 | ||
| Smoking Cessation Drug Therapy | 275 | ||
| Respiratory Care Assessment of Smoking Cessation Drug Therapy | 278 | ||
| Nitric Oxide | 278 | ||
| Respiratory Care Assessment of Nitric Oxide | 281 | ||
| Synthetic Analogues of Prostacyclin (PGI₂) | 281 | ||
| Respiratory Care Assessment of Synthetic Analogues of Prostacyclin (PGI₂) | 282 | ||
| References | 283 | ||
| Chapter 17 Neonatal and Pediatric Aerosolized Drug Therapy | 285 | ||
| Off-Label Use of Drugs in Neonatal and Pediatric Patients | 286 | ||
| Factors Affecting Neonatal and Pediatric Aerosol Drug Delivery | 287 | ||
| Nebulized Drug Distribution | 289 | ||
| Clinical Response to Aerosolized Drugs in Neonatal and Pediatric Patients | 291 | ||
| Selection of Delivery Devices | 291 | ||
| Compliance and Cooperation during Aerosol Therapy | 293 | ||
| Aerosol Administration in Intubated Neonatal and Pediatric Patients | 294 | ||
| Summary | 294 | ||
| References | 295 | ||
| UNIT THREE Critical Care, Cardiovascular, and Polysomnography Agents | 298 | ||
| Chapter 18 Skeletal Muscle Relaxants (Neuromuscular Blocking Agents) | 299 | ||
| Uses of Neuromuscular Blocking Agents | 300 | ||
| Physiology of the Neuromuscular Junction | 300 | ||
| Nondepolarizing Agents | 301 | ||
| Depolarizing Agents | 305 | ||
| Neuromuscular Blocking Agents and Mechanical Ventilation | 306 | ||
| Monitoring of Neuromuscular Blockade | 309 | ||
| Future of Neuromuscular Blocking Agents and Reversal | 311 | ||
| References | 312 | ||
| Chapter 19 Diuretic Agents | 313 | ||
| Renal Structure and Function | 314 | ||
| Diuretic Groups | 315 | ||
| Diuretic Combinations | 319 | ||
| Drug Interactions | 319 | ||
| Adverse Effects | 320 | ||
| Special Situations | 321 | ||
| References | 323 | ||
| Chapter 20 Drugs Affecting the Central Nervous System | 325 | ||
| Neurotransmitters | 327 | ||
| Psychiatric Medications | 328 | ||
| Ethyl Alcohol | 332 | ||
| Pain Treatment | 332 | ||
| Chronic Pain Syndromes | 337 | ||
| Anesthesia | 337 | ||
| Central Nervous System and Respiratory Stimulants | 340 | ||
| References | 342 | ||
| Chapter 21 Vasopressors, Inotropes, and Antiarrhythmic Agents | 343 | ||
| Overview of Cardiovascular System | 344 | ||
| Agents Used in the Management of Shock | 348 | ||
| Electrophysiology of Myocardium | 350 | ||
| Pharmacology of Antiarrhythmics | 351 | ||
| Management and Pharmacotherapy of Advanced Cardiac Life Support | 362 | ||
| Alternative Routes of Medication Administration | 365 | ||
| References | 366 | ||
| Chapter 22 Drugs Affecting Circulation: Antihypertensives, Antianginals, Antithrombotics | 367 | ||
| Hypertension | 368 | ||
| Hypertension Pharmacotherapy | 370 | ||
| Angina | 381 | ||
| Antithrombotic Agents | 384 | ||
| References | 397 | ||
| Chapter 23 Sleep and Sleep Pharmacology | 399 | ||
| History of Treatment of Sleep Disorders | 400 | ||
| Progression of Sleep | 401 | ||
| Neurophysiologic Mechanisms | 402 | ||
| Sleep Disorders: Causes and Treatments | 410 | ||
| References | 415 | ||
| Appendix A Units and Systems of Measurement | 417 | ||
| Appendix B Acceptable Mixtures of Most Commonly Prescribed Respiratory Care Drugs | 421 | ||
| Glossary of Selected Terms | 422 | ||
| Index | 444 |